Clinical Efficacy and Safety of Cefuroxime Sodium+Ambroxol in the Treatment of Chronic Bronchitis Complicated with Emphysema
Objective To observe the clinical efficacy and safety of cefuroxime sodium+ambroxol in the treatment of chronic bronchitis complicated with emphysema.Methods A total of 80 patients with chronic bronchitis complicated with emphysema who were diagnosed and treated in our hospital from March 2019 to March 2022 were selected as the research objects.They were divided into control group and observation group by random number table method,with 40 patients in each group.The control group was treated with cefuroxime sodium,and the observation group was treated with ambroxol on the basis of the control group.The total effective rate,clinical symptom improvement time,inflammatory factor level,blood gas index and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group(95.00％)was higher than that in the control group(82.50％)(P＜0.05).The time of lung X-ray recovery,body temperature recovery and hospitalization in the observation group were shorter than those in the control group(P＜0.05).After treatment,interleukin-8(IL-8)and tumor necrosis factor-α(TNF-α)in the two groups were lower than those before treatment,and those in the observation group were lower than those in the control group(P＜0.05).After treatment,PaO2 in the two groups was higher than that before treatment,PaCO2 was lower than that before treatment,and PaO2 in the observation group was higher than that in the control group,PaCO2 was lower than that in the control group(P＜0.05).There was no significant difference in the incidence of adverse reactions between the observation group and the control group(P＞0.05).Conclusion Cefuroxime sodium+ambroxol can improve the clinical efficacy of chronic bronchitis complicated with emphysema,improve the blood gas index,reduce clinical symptoms,reduce the level of inflammatory factors,and has high clinical application value.
国家科技期刊平台
NSTL
万方数据
维普
